close

Clinical Trials

Date: 2011-01-28

Type of information:

phase: 3

Announcement: recruitment of the first patient

Company: AB Science (France)

Product: masitinib

Action mechanism: tyrosine kinase inhibitor

Disease: secondary acute myeloid leukaemia

Therapeutic area: Cancer Oncology

Country: 60 centres around the world

Trial details:

Latest news:

Is general: Yes